Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedA dedicated Locations section has been added with Zhejiang listed as the site. The page revision is updated to v3.3.3, and the old Zhejiang Locations entry plus the HHS Vulnerability Disclosure link have been removed.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page; this is a minor system update and does not affect the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedRemoved the generic government funding/status notice from the page; core study details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check60 days agoChange DetectedNo significant changes detected on the Study Details page between the two screenshots.SummaryDifference0.5%

- Check89 days agoChange Detected- Updated the page to v3.2.0 and added a government-operational status notice clarifying potential delays and open status of NIH Clinical Center. - Removed the previous version tag v3.1.0.SummaryDifference4%

- Check96 days agoChange DetectedPage version updated from v3.0.2 to v3.1.0 with an added contact-like string (+86-571-87235147); no changes to core content, pricing, or availability inferred.SummaryDifference0.1%

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.